EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

Therapeutic Peptide SS ‐31 Modulates Membrane Binding and Aggregation of α‐Synuclein and Restores Impaired Mitochondrial Function

Ewelina Stefaniak iD, Beiyuan Cui, Xucheng Yan iD, Kexin Sun, Xiangyu Teng, Liming Ying iD

Chemical Biology & Drug Design · 2026-06 · 107 (6)

DOI: 10.1111/cbdd.70332 ↗

At a glance

Journal article in Chemical Biology & Drug Design, published online on 2026-05-31. Written by Ewelina Stefaniak and 5 co-authors. Institution: National Heart and Lung Institute, Imperial College London, Molecular Sciences Research Hub, London, UK. Major MEDLINE topics: alpha-Synuclein, Mitochondria, Oligopeptides. Cited 1 times so far (Crossref); 91 references. The full text is freely available (open access, CC BY 4.0). Funded by: The Leverhulme Trust, Biotechnology and Biological Sciences Research Council, Horizon 2020 Framework Programme.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Membrane binding and aggregation properties of α‐synuclein are closely associated with Parkinson's disease and a class of related syndromes named as synucleinopathy. This study explored the potential of SS‐31 (Elamipretide), a therapeutic tetrapeptide with alternating cationic and aromatic residues and known properties of mitochondrial inner membrane binding and oxidative stress reduction, in modulating α‐synuclein interaction with the lipid membranes and mitigating the impairment of mitochondrial function induced by α‐synuclein oligomers. It was demonstrated by both fluorescence correlation spectroscopy and fluorescence anisotropy that SS‐31 displaces both wild‐type and N‐terminal acetylated α‐synuclein from negatively charged small unilamellar vesicles in a dose‐dependent manner. Thioflavin‐T assay and transmission electron microscopy showed that SS‐31 inhibits membrane‐induced α‐synuclein aggregation and alters the morphology of α‐synuclein fibrils. Moreover, MTT assay and Seahorse Mito Stress Test indicated that SS‐31 enhances cell viability and restores impaired mitochondrial function in α‐synuclein oligomer‐treated neuroblastoma cells. Finally, confocal imaging revealed that SS‐31 hinders cellular uptake of α‐synuclein oligomers, possibly by modifying cell membrane electrostatics. These findings suggest that SS‐31 potentially attenuates α‐synuclein induced mitochondrial impairment via its interaction with the lipid membranes, justifying further development of a peptide‐based intervention against α‐synuclein mediated pathology.

Subjects

MeSH terms (MEDLINE)

alpha-SynucleinMitochondriaOligopeptidesHumansCell Line, TumorCell SurvivalProtein BindingProtein AggregatesUnilamellar Liposomes

Author keywords

SS‐31 peptidelipid membranemitochondrial functionα‐Synuclein

Substances

alpha-SynucleinOligopeptideselamipretideProtein AggregatesUnilamellar Liposomes

Authors and institutions

  • National Heart and Lung Institute, Imperial College London, Molecular Sciences Research Hub, London, UK.
  • Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
  • Department of Chemistry, Imperial College London, Molecular Sciences Research Hub, London, UK.

ORCID profiles: Ewelina Stefaniak, Xucheng Yan, Liming Ying

Funding

  • The Leverhulme Trust
  • Biotechnology and Biological Sciences Research Council
  • Horizon 2020 Framework Programme
  • Leverhulme Trust

Cite

APA

Stefaniak, E., Cui, B., Yan, X., Sun, K., Teng, X., & Ying, L. (2026). Therapeutic Peptide SS ‐31 Modulates Membrane Binding and Aggregation of α‐Synuclein and Restores Impaired Mitochondrial Function. Chemical Biology & Drug Design, 107(6). https://doi.org/10.1111/cbdd.70332

Vancouver

Stefaniak E, Cui B, Yan X, Sun K, Teng X, Ying L. Therapeutic Peptide SS ‐31 Modulates Membrane Binding and Aggregation of α‐Synuclein and Restores Impaired Mitochondrial Function. Chemical Biology & Drug Design. 2026;107(6). doi:10.1111/cbdd.70332

BibTeX
@article{Stefaniak2026,
  author = {Stefaniak, Ewelina and Cui, Beiyuan and Yan, Xucheng and Sun, Kexin and Teng, Xiangyu and Ying, Liming},
  title = {Therapeutic Peptide SS ‐31 Modulates Membrane Binding and Aggregation of α‐Synuclein and Restores Impaired Mitochondrial Function},
  journal = {Chemical Biology & Drug Design},
  year = {2026},
  volume = {107},
  number = {6},
  doi = {10.1111/cbdd.70332}
}
Start for free →